FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours ner resnonse.	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add <u>Li Zhen</u>	ress of Report	Requiring Stater	2. Date of Event Requiring Statement (Month/Day/Year) 01/25/2018 3. Issuer Name and Ticker or Trading Symbol ARROWHEAD PHARMACEUTICALS, INC. [ARWR]							VR]		
(Last) 225 S. LAKE SUITE 1050 (Street) PASADENA (City)		(Middle) 91101 (Zip)	_			s all applicable) Director Officer (give title below)	Director 10% Owner Officer (give title Other (spec		5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(9)	(2.5)	(Table I - Nor	-Derivat	tive S	ecurities Beneficial	ly Owned					
1. Title of Security (Instr. 4) Common Stock					2. Amount of Securities Beneficially Owned (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
						urities Beneficially options, convertible		s)				
1. Title of Derivative Security (Instr. 4)			Expiration Da	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (I		4. Convers	cise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivati Security	ive	Direct (D) or Indirect (I) (Instr. 5)		
Stock Option			03/27/2014 ⁽²⁾	03/27/2024	4	Common Stock	60,000	16.3	3	D		
Stock Option			12/10/2014 ⁽²⁾	12/10/2024	4	Common Stock	47,500	5.45	5	D		
Stock Option			01/01/2016 ⁽²⁾	01/01/2026	6	Common Stock	50,000	6.15	5	D		

Explanation of Responses:

- 1. Includes a total of 150,000 shares underlying restricted stock units. 85,000 of these restricted stock units will vest in January 2019, and the remaining 65,000 will vest in 4 equal annual tranches beginning in January 2019.
- 2. Option vests and becomes exercisable over a four year period from date of grant.

Remarks:

<u>/s/ Zhen Li</u>

01/29/2018

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.